A Phase 4 interventional study of MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks and Comparator: Fluticasone / Duration of Treatment: 6 Weeks in Asthma, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 399 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Organon and Co is the lead sponsor of 478 studies on the registry; none are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 17 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Canadian asthma guidelines criteria
Asthma control questionnaire
No study locations are listed for this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Organon and Co